Circulation Heart Failure · 2010 · 103 citations · 32 references
Life SciencesCardiologyEndocrinologyCell SignalingCellular BiochemistrySignal TransductionG Protein-coupled Receptor SignalingGlucagon-like Peptide-1 Receptor AgonistsPancreatic HormonesAdenylyl Cyclase SignalingGlucagon-like Peptide 1 Receptor AgonismGlucagon-like Peptide 1 SignalingGlucagon-like Peptide-1 Receptor SignalingGlucagon-like PeptidesNitric OxideP38 Mitogen-activated Protein Kinase SignalingReceptors
BACKGROUND: We have shown that glucagon-like peptide-1 (GLP-1[7-36] amide) stimulates myocardial glucose uptake in dilated cardiomyopathy (DCM) independent of an insulinotropic effect. The cellular mechanisms of GLP-1-induced myocardial glucose uptake are unknown. METHODS AND RESULTS: Myocardial substrates and glucoregulatory hormones were measured in conscious, chronically instrumented dogs at control (n=6), DCM (n=9) and DCM after treatment with a 48-hour infusion of GLP-1 (7-36) amide (n=9) or vehicle (n=6). GLP-1 receptors and cellular pathways implicated in myocardial glucose uptake were measured in sarcolemmal membranes harvested from the 4 groups. GLP-1 stimulated myocardial glucose uptake (DCM: 20+/-7 nmol/min/g; DCM+GLP-1: 61+/-12 nmol/min/g; P=0.001) independent of increased plasma insulin levels. The GLP-1 receptors were upregulated in the sarcolemmal membranes (control: 98+/-2 density units; DCM: 256+/-58 density units; P=0.046) and were expressed in their activated (65 kDa) form in DCM. The GLP-1-induced increases in myocardial glucose uptake did not involve adenylyl cyclase or Akt activation but was associated with marked increases in p38alpha MAP kinase activity (DCM+vehicle: 97+/-22 pmol ATP/mg/min; DCM+GLP-1: 170+/-36 pmol ATP/mg/min; P=0.051), induction of nitric oxide synthase 2 (DCM+vehicle: 151+/-13 density units; DCM+GLP-1: 306+/-12 density units; P=0.001), and GLUT-1 translocation (DCM+vehicle: 21+/-3% membrane bound; DCM+GLP-1: 39+/-3% membrane bound; P=0.005). The effects of GLP-1 on myocardial glucose uptake were blocked by pretreatment with the p38alpha MAP kinase inhibitor or the nonspecific nitric oxide synthase inhibitor nitro-l-arginine. CONCLUSIONS: GLP-1 stimulates myocardial glucose uptake through a non-Akt-1-dependent mechanism by activating cellular pathways that have been identified in mediating chronic hibernation and the late phase of ischemic preconditioning.
32
Kiwon Ban, M. Hossein Noyan-Ashraf, Judith Hoefer et al. · Circulation · 2008 · 1K citations
Medicine, Cardiology, Pharmacology +17
Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Amal Bose, Mihaela Mocanu, Richard D. Carr et al. · Diabetes · 2005 · 628 citations · Full text
Lazaros A. Nikolaidis, Dariush Elahi, Teresa Hentosz et al. · Circulation · 2004 · 512 citations · Full text
Medicine, Cardiology, Endocrinology +17